HRX-0233 / HepaRegeniX, Netherlands Cancer Institute-Antoni van Leeuwenhoek - LARVOL DELTA

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers. (PubMed, Proc Natl Acad Sci U S A) - "We find that the combination of sotorasib, a drug targeting KRASG12C, and the MAP2K4 inhibitor HRX-0233 prevents this feedback activation and is highly synergistic in a panel of KRASG12C-mutant lung and colon cancer cells. Moreover, combining HRX-0233 and sotorasib is well-tolerated and resulted in durable tumor shrinkage in mouse xenografts of human lung cancer cells, suggesting a therapeutic strategy for KRAS-driven cancers."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Solid Tumor • KRAS • MAP2K4

"René Bernards - Q: HRX-0233 (MKK4) + SHP2 combination tested A: 200 animals are currently treated #AACR22" (@gerlach_d)

Oncology • MAP2K4

HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy (PipelineReview) - "HepaRegeniX GmbH...a collaboration with the Netherlands Cancer Institute (NKI) to investigate HepaRegeniX’ new drug candidate HRX-0233 in preclinical in vivo models with Kirsten rat sarcoma virus (KRAS) mutant tumors. Under the partnership, NKI will conduct the preclinical research to find the most promising combinations of the small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4) with other inhibitors of the MAP kinase pathway."

Licensing / partnership